Hikma To Buy Boehringer's U.S. Injectables Business In $300 Million Deal
This article was originally published in PharmAsia News
Executive Summary
Hikma Pharmaceuticals said Boehringer Ingelheim has agreed to sell its U.S. injectable drugs business for as much as $300 million, the Jordan-based company to pay $225 million up front.